PDS Biotechnology Free Cash Flow Per Share Over Time
| PDSB Stock | USD 2.19 0.04 1.86% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out PDS Biotechnology Performance and PDS Biotechnology Correlation. PDS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Per Share Analysis
Compare PDS Biotechnology Corp and related stocks such as Mereo BioPharma Group, Terns Pharmaceuticals, and Inozyme Pharma Free Cash Flow Per Share Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MREO | (0.6118) | (0.6118) | (0.6118) | (0.6118) | (0.6118) | (0.6118) | (0.6118) | (0.4991) | (0.3257) | (0.5143) | (0.084) | (0.0109) | (0.0644) | (0.0327) | (0.0343) |
| TERN | (0.764) | (0.764) | (0.764) | (0.764) | (0.764) | (0.764) | (0.764) | (0.764) | (0.764) | (2.6745) | (1.2097) | (1.6687) | (1.3705) | (0.9464) | (0.99) |
| INZY | (0.6405) | (0.6405) | (0.6405) | (0.6405) | (0.6405) | (0.6405) | (0.6405) | (0.6405) | (0.6405) | (1.25) | (1.5626) | (2.0608) | (1.5404) | (1.3691) | (1.44) |
| HOOK | (0.8092) | (0.8092) | (0.8092) | (0.8092) | (0.8092) | (0.8092) | (0.8092) | (0.8092) | (1.0505) | (2.4485) | (15.9906) | (23.8912) | (3.8148) | (6.5255) | (6.85) |
| ENVB | (679) | (22.9026) | (18.7547) | (16.326) | (32.5766) | (2.3 K) | (2.4 K) | (916) | (539) | (95.9884) | (34.1783) | (26.0879) | (12.262) | (6.5304) | (6.86) |
| OCEA | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0032) | (0.0796) | (0.0205) | (0.0235) | (0.0247) |
| XFOR | (11.8383) | (11.8383) | (11.8383) | (11.8383) | (11.8383) | (11.8383) | (23.3964) | (81.2272) | (89.1874) | (4.1829) | (2.9975) | (2.7776) | (1.2153) | (0.5431) | (0.57) |
| DAWN | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.0729) | (0.2193) | (0.9126) | (1.6787) | (1.8813) | (1.98) |
| ELEV | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.2294) | (0.5206) | (1.3) | (3.6777) | (1.6486) | (1.73) |
PDS Biotechnology Corp and related stocks such as Mereo BioPharma Group, Terns Pharmaceuticals, and Inozyme Pharma Free Cash Flow Per Share description
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.My Equities
My Current Equities and Potential Positions
| PDS Biotechnology Corp | PDSB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.19
Check out PDS Biotechnology Performance and PDS Biotechnology Correlation. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
PDS Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.